Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.55 |
| ▸ | TTR | P02766 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533931 | 0.91 | MAPT (0.54) | MAOAKDM4EMAPTALDH1A1GLA | |
| SCHEMBL1784133 | 0.90 | MAOA (0.62) | MAOAKDM4EMAPTALDH1A1GLA | |
| SCHEMBL24241564 | 0.82 | MAOA (0.56) | MAOAKDM4EMAPTALDH1A1GLA | |
| SCHEMBL30367521 | 0.81 | CYP2A6 (0.45) | KDM4EMAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6856438 | 0.81 | CYP2A6 (0.45) | KDM4EMAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1420897 | 0.80 | MAPT (0.53) | MAOAKDM4EMAPTALDH1A1GLA | |
| SCHEMBL28257333 | 0.80 | MAOA (0.69) | MAOAKDM4EMAPTALDH1A1GLA | |
| SCHEMBL28259686 | 0.80 | MAOA (0.53) | MAOAKDM4EMAPTALDH1A1GLA | |
| SCHEMBL28257336 | 0.80 | MAOA (0.69) | MAOAKDM4EMAPTALDH1A1GLA | |
| SCHEMBL28259688 | 0.80 | MAOA (0.53) | MAOAKDM4EMAPTALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8323750-B2 | Method of ultraviolet light assisted surface modification and product having a surface formed by this method | BEIJING WANHEXINYUAN BIOTECHNOLOGY CO., LTD. (CN) | 2012-12-04 | — | — | US | disclosed |
| US-20110124766-A1 | METHOD OF ULTRAVIOLET LIGHT ASSISTED SURFACE MODIFICATION AN PRODUCT HAVING A SURFACE FORMED BY THIS METHOD | BEIJING WANHEXINYUAN BIOTECHNOLOGY CO., LTD. (CN) | 2011-05-26 | — | — | US | disclosed |
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| CN-101039940-A | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2007-09-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | OPRD1, OPRK1, OPRM1 | MAOA 1245/4885KDM4E 1763/4885MAPT 1930/4885 |
| US-20110124766-A1 | METHOD OF ULTRAVIOLET LIGHT ASSISTED SURFACE MODIFICATION AN PRODUCT HAVING A SURFACE FORMED BY THIS METHOD | XPA, CYBA, PROC | MAOA 34/4885KDM4E 1160/4885MAPT 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.